Combining Cagrilintide and Semaglutide for Diabesity Prevention.

Coadministration of cagrilintide and semaglutide, dubbed CagriSema, resulted in significant weight loss and improved glucose control in a phase 2 trial of patients with type 2 diabetes. The combination drug had a synergistic effect for both glycemic control and weight loss, with a magnitude not previously reported with pharmacotherapies in this population. The study suggests that combination metabolic hormonal therapy could offer weight reduction, remission of type 2 diabetes, and reduced cardiovascular mortality in the near future. However, more patients are needed for further investigation in longer and larger phase 3 studies.